RT @IHSMarkit: "If you want to take care of shareholders, you better take care of your people, and you better take care of your planet, and…
IHS examines the global experience with risk sharing agreements in recent conference presentation
Last week I presented, with IHS colleague Sarika Pundit, about the global experience with risk sharing agreements at the CBI Reimbursement and Contracting conference in Philadelphia. Among other things, we examined the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of finance-based agreements. The therapeutic areas most likely to be affected by risk sharing were also reviewed, along with recent regulatory developments that could encourage greater utilisation of risk sharing deals. The analysis was based on the IHS Risk Sharing database and our Payer Partnerships Multi Client study, with additional insights provided from risk sharing coverage in our Same Day Analysis service, Special reports and the IHS International Reference Pricing (IRP) matrix. An abbreviated version of the presentation is available below.
Milena Izmirlieva is the head of the life sciences research team at IHS
Posted 3 March 2015
- The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September
- Is the US ready to start relaxing COVID-19 lockdowns?
- COVID-19 could cause delays for price framework agreements in parts of Europe
- US scrambles for resources in COVID-19 response
- COVID-19: Risk of severe complications among the United States health workforce
- COVID-19 pandemic: Health system surge capacity
- UK bans parallel export of two COVID-19 treatment candidates to protect national supply
- China’s young biosimilars sector
The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September https://t.co/9fX4R1K8rC